G6PD and lung adenocarcinoma: Nagashio et al. (2019) reported that the survival rate of lung adenocarcinoma patients with G6PD upregulation in the invasive frontier was significantly lower than those without G6PD upregulation. Multivariate analysis further showed that G6PD expression is an independent factor for patient prognosis (Nagashio et al., 2019).